Myeloma
Myeloma, commonly referred to as multiple myeloma, is a blood cancer that develops from plasma cells. It can be benign or malignant. In the UK, there are approximately 17,500 myeloma patients at any given moment. It is responsible for 2% of all malignancies and 15% of blood cancers. Myeloma primarily affects those over 65, but it has been identified in those as young as 20.
- Multiple Myeloma
- Signal Transduction
- Metastatic Cancer
- Hematologic Cancer
- Signaling Pathway
- Information on Drugs
- Medicine for Inflammation
Related Conference of Myeloma
Myeloma Conference Speakers
Recommended Sessions
- Anemia
- Biomarkers in Hematology
- Bleeding Disorders
- Clinical and Experimental Hematology
- Coagulopathies
- Gene and Cell Therapies for Blood Disorders
- Hematologic Malignancies
- Hematology and neurological disorders
- Hematology in COVID-19 patients
- Hematology in Pediatrics
- Hematology-oncology
- Hematopoietic Stem Cell Transplantation
- Hemostasis
- HIV/AIDS
- Immunohematology
- Immunotherapy for Blood Disorders
- Leukemia
- Myeloma
- Rare Blood Disorders
- Thalassemia
- Thrombosis and Hemostasis

